109 related articles for article (PubMed ID: 36087164)
1. Phase I study to evaluate of the gastric pH-dependent drug interaction between famitinib and the proton pump inhibitor omeprazole in healthy subjects.
Hu L; Cai M; Qian W; Dou T; Sun Q; Tang L; Wang H
Invest New Drugs; 2022 Dec; 40(6):1274-1281. PubMed ID: 36087164
[TBL] [Abstract][Full Text] [Related]
2. CYP3A inhibitor itraconazole affect pharmacokinetic behavior of famitinib and its active metabolite: results of a single-center, single-arm, open-label and fixed sequence study.
Huang Y; Jia Y; Chen X; Wang C; Wang Y; Wang M; Wu P; Shen J
Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):1005-1013. PubMed ID: 38053514
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers.
Li L; Xiang YX; Yang GP; Zhang XF; Yang XY; Yang S; Huang J
Invest New Drugs; 2021 Jun; 39(3):796-802. PubMed ID: 33420642
[TBL] [Abstract][Full Text] [Related]
4. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
Kletzl H; Giraudon M; Ducray PS; Abt M; Hamilton M; Lum BL
Anticancer Drugs; 2015 Jun; 26(5):565-72. PubMed ID: 25643050
[TBL] [Abstract][Full Text] [Related]
5. Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects.
Hu L; Dou T; Sun Q; Tang L; Cai M; Qian W; Wang H
Invest New Drugs; 2023 Apr; 41(2):276-283. PubMed ID: 36800130
[TBL] [Abstract][Full Text] [Related]
6. The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects.
Li T; Li X; Jiang X; Wang C; Sun F; Liu Y; Lin P; Shi P; Fu Y; Gao X; Zhang Y; Cao Y
Cancer Chemother Pharmacol; 2022 Nov; 90(5):409-415. PubMed ID: 36107220
[TBL] [Abstract][Full Text] [Related]
7. Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects.
Groenendaal-van de Meent D; den Adel M; van Dijk J; Barroso-Fernandez B; El Galta R; Golor G; Schaddelee M
Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):685-692. PubMed ID: 29752643
[TBL] [Abstract][Full Text] [Related]
8. Clinical study of drug-drug interaction between omeprazole and pyrotinib after meal.
Li X; Wang Y; Zhu X; Zheng L
Br J Clin Pharmacol; 2022 May; 88(5):2349-2358. PubMed ID: 34873745
[TBL] [Abstract][Full Text] [Related]
9. Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects.
Small DS; Royalty J; Cannady EA; Hale C; Wang MD; Downs D; Suico JG
Pharmacotherapy; 2016 Jul; 36(7):749-56. PubMed ID: 27284735
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Omeprazole, a Proton Pump Inhibitor, in Healthy Subjects.
Trivedi A; Sohn W; Jafarinasabian P; Zhang H; Terminello B; Flach S; Abbasi S; Dutta S; Lee E
Clin Pharmacol Drug Dev; 2022 Jan; 11(1):129-133. PubMed ID: 34272833
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers.
Vishwanathan K; Dickinson PA; Bui K; Cassier PA; Greystoke A; Lisbon E; Moreno V; So K; Thomas K; Weilert D; Yap TA; Plummer R
J Clin Pharmacol; 2018 Apr; 58(4):474-484. PubMed ID: 29178442
[TBL] [Abstract][Full Text] [Related]
12. Effect of an Antacid (Aluminum Hydroxide/Magnesium Hydroxide/Simethicone) or a Proton Pump Inhibitor (Omeprazole) on the Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) in Healthy Adult Subjects.
Patel G; Gupta VK; Gasink L; Bajraktari F; Lei Y; Jain A; Srivastava P; Talley AK
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0149522. PubMed ID: 36943038
[TBL] [Abstract][Full Text] [Related]
13. Effects of omeprazole and ritonavir on absorption and elimination of the hepatitis C virus NS5A inhibitor GSK2336805 in healthy adults.
Adkison KK; Jones LS; Lou Y; Gan J; Wilfret DA
Clin Pharmacol Drug Dev; 2014 Sep; 3(5):338-45. PubMed ID: 27129005
[TBL] [Abstract][Full Text] [Related]
14. Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects.
Fang AF; Damle BD; LaBadie RR; Crownover PH; Hewlett D; Glue PW
Pharmacotherapy; 2008 Jan; 28(1):42-50. PubMed ID: 18154473
[TBL] [Abstract][Full Text] [Related]
15. Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects.
Chong E; Kalia V; Willsie S; Winkle P
J Nephrol; 2014 Dec; 27(6):659-66. PubMed ID: 24699894
[TBL] [Abstract][Full Text] [Related]
16. A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide.
Bækdal TA; Breitschaft A; Navarria A; Hansen CW
Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):869-877. PubMed ID: 29897249
[TBL] [Abstract][Full Text] [Related]
17. Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole.
de Kanter CT; Colbers AP; Blonk MI; Verweij-van Wissen CP; Schouwenberg BJ; Drenth JP; Burger DM
J Antimicrob Chemother; 2013 Jun; 68(6):1415-22. PubMed ID: 23429642
[TBL] [Abstract][Full Text] [Related]
18. The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposure.
de Jong J; Haddish-Berhane N; Hellemans P; Jiao J; Sukbuntherng J; Ouellet D
Cancer Chemother Pharmacol; 2018 Aug; 82(2):299-308. PubMed ID: 29882017
[TBL] [Abstract][Full Text] [Related]
19. Effect of icosapent ethyl (eicosapentaenoic acid ethyl ester) on omeprazole plasma pharmacokinetics in healthy adults.
Braeckman RA; Stirtan WG; Soni PN
Drugs R D; 2014 Sep; 14(3):159-64. PubMed ID: 24973042
[TBL] [Abstract][Full Text] [Related]
20. No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine.
Elshoff JP; Cawello W; Andreas JO; Braun M
Clin Pharmacol Drug Dev; 2014 May; 3(3):187-93. PubMed ID: 27128608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
